Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children

Clinics in Liver Disease

Volumn 20, Issue 2, 2016, Pages 293-312

  Kleiner, David E ^a   Makhlouf, Hala R ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Histology; Liver biopsy; Scoring; Staging; Steatohepatitis; Steatosis

Indexed keywords

CARNITINE DEFICIENCY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; ECHOGRAPHY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; REVIEW; REYE SYNDROME; ADOLESCENT; ADULT; BIOPSY; CHILD; LIVER; OBSERVER VARIATION; PATHOLOGY;

ADOLESCENT; ADULT; BIOPSY; CHILD; HUMANS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBSERVER VARIATION;

EID: 84951755323     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.10.011     Document Type: Review

References (94)

1. Sanyal A.J., Brunt E.M., Kleiner D.E., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54(1):344-353.
2. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36(6):1349-1354.
3. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144(10):705-714.
4. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
5. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28(4):339-350.
6. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
7. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923.
8. Brunt E.M., Ramrakhiani S., Cordes B.G., et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003, 16(1):49-56.
9. Vuppalanchi R., Gould R.J., Wilson L.A., et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012, 6:379-385.
10. Cotler S.J., Kanji K., Keshavarzian A., et al. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2004, 38(9):801-804.
11. Adams L.A., Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2007, 11(1):25-35. viii.
12. Brunt E.M. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009, 13(4):533-544.
13. Nakano M., Fukusato T. Histological study on comparison between NASH and ALD. Hepatol Res 2005, 33(2):110-115.
14. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
15. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22(6):1714-1719.
16. Noureddin M., Lam J., Peterson M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013, 58(6):1930-1940.
17. Cassidy F.H., Yokoo T., Aganovic L., et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics 2009, 29(1):231-260.
18. Neuschwander-Tetri B.A., Clark J.M., Bass N.M., et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010, 52(3):913-924.
19. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44(1):27-33.
20. Sorbi D., McGill D.B., Thistle J.L., et al. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000, 95(11):3206-3210.
21. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
22. Kleiner D.E., Berk P.D., Hsu J.Y., et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) study. Semin Liver Dis 2014, 34(1):98-107.
23. Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012, 32(1):3-13.
24. Chalasani N., Wilson L., Kleiner D.E., et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008, 48(5):829-834.
25. Seki S., Kitada T., Yamada T., et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002, 37(1):56-62.
26. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2009, 49(3):809-820.
27. Gadd V.L., Skoien R., Powell E.E., et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology 2014, 59(4):1393-1405.
28. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101(2):368-373.
29. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004, 39(6):1647-1654.
30. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38(4):1008-1017.
31. Guy C.D., Suzuki A., Burchette J.L., et al. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol 2012, 43(6):790-800.
32. Gramlich T., Kleiner D.E., McCullough A.J., et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004, 35(2):196-199.
33. Zatloukal K., French S.W., Stumptner C., et al. From Mallory to Mallory-Denk bodies: what, how and why?. Exp Cell Res 2007, 313(10):2033-2049.
34. Charlton M., Kasparova P., Weston S., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001, 7(7):608-614.
35. Abdelmalek M., Ludwig J., Lindor K.D. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995, 20(2):127-130.
36. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11(1):74-80.
37. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29(3):664-669.
38. Poonawala A., Nair S.P., Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000, 32(4 Pt 1):689-692.
39. Struben V.M., Hespenheide E.E., Caldwell S.H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000, 108(1):9-13.
40. Caldwell S.H., Swerdlow R.H., Khan E.M., et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999, 31(3):430-434.
41. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295(13):1549-1555.
42. Patton H.M., Lavine J.E., Van Natta M.L., et al. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008, 135(6):1961-1971.e1962.
43. Carter-Kent C., Yerian L.M., Brunt E.M., et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009, 50(4):1113-1120.
44. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94(9):2467-2474.
45. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
46. Bedossa P., Poitou C., Veyrie N., et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012, 56(5):1751-1759.
47. Bedossa P., Consortium F.P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014, 60(2):565-575.
48. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38(6):1449-1457.
49. Scheuer P.J. Liver biopsy size matters in chronic hepatitis: bigger is better. Hepatology 2003, 38(6):1356-1358.
50. Goldstein N.S., Hastah F., Galan M.V., et al. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. Am J Clin Pathol 2005, 123(3):382-387.
51. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128(7):1898-1906.
52. Younossi Z.M., Gramlich T., Liu Y.C., et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998, 11(6):560-565.
53. Drenick E.J., Simmons F., Murphy J.F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970, 282(15):829-834.
54. Popper H., Schaffner F. Editorial: steatosis-Mallory's hyaline-cirrhosis: can their relationships be resolved by an experiment of nature?. Gastroenterology 1974, 67(1):185-188.
55. Thaler H. Editorial: fatty liver-steatonecrosis-cirrhosis. Acta Hepatogastroenterol (Stuttg) 1975, 22(5):271-273.
56. Argo C.K., Northup P.G., Al-Osaimi A.M., et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009, 51(2):371-379.
57. Singh S., Allen A.M., Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015, 13(4):643-654.e1-9. [quiz: e639-40].
58. McPherson S., Hardy T., Henderson E., et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015, 62(5):1148-1155.
59. Pais R., Charlotte F., Fedchuk L., et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013, 59(3):550-556.
60. Angulo P., Kleiner D.E., Dam-Larsen S., et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015, 149(2):389-397.e10.
61. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989, 20(6):594-598.
62. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107(4):1103-1109.
63. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118(6):1117-1123.
64. Evans C.D., Oien K.A., MacSween R.N., et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?. J Clin Pathol 2002, 55(9):689-692.
65. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98(9):2042-2047.
66. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004, 40(4):820-826.
67. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42(1):132-138.
68. Hui A.Y., Wong V.W., Chan H.L., et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005, 21(4):407-413.
69. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
70. Caldwell S.H., Lee V.D., Kleiner D.E., et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol 2009, 8(4):346-352.
71. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58(11):1538-1544.
72. Sorrentino P., Terracciano L., D'Angelo S., et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol 2010, 105(2):336-344.
73. Wong V.W., Wong G.L., Choi P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59(7):969-974.
74. Hamaguchi E., Takamura T., Sakurai M., et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010, 33(2):284-286.
75. Pais R., Pascale A., Fedchuck L., et al. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2011, 35(1):23-28.
76. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98(11):2485-2490.
77. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3):770-778.
78. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355(22):2297-2307.
79. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006, 4(12):1537-1543.
80. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135(4):1176-1184.
81. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135(1):100-110.
82. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50(6):1818-1826.
83. Haukeland J.W., Konopski Z., Eggesbo H.B., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44(7):853-860.
84. Nelson A., Torres D.M., Morgan A.E., et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009, 43(10):990-994.
85. Leuschner U.F., Lindenthal B., Herrmann G., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(2):472-479.
86. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
87. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18):1675-1685.
88. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305(16):1659-1668.
89. Van Wagner L.B., Koppe S.W., Brunt E.M., et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011, 10(3):277-286.
90. Zein C.O., Yerian L.M., Gogate P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011, 54(5):1610-1619.
91. Wong V.W., Wong G.L., Chan A.W., et al. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial. J Gastroenterol Hepatol 2013, 28(1):57-62.
92. Sanyal A.J., Abdelmalek M.F., Suzuki A., et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014, 147(2):377-384.e1.
93. Takeshita Y., Takamura T., Honda M., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014, 57(5):878-890.
94. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385(9972):956-965.